The trial investigated five ascending doses of PXS25 in 40 subjects. At all doses, PXS25 was found to be safe and well tolerated with a pharmacokinetic profile consistent with a drug, that could be delivered once per day.
Alan Robertson, chief executive officer of Pharmaxis, said: “We have seen encouraging results from PXS25 in pre clinical testing that suggests it will be active in a range of fibrotic diseases. I am therefore delighted that, based on the results from this Phase I study, PXS25 fulfils many of the other criteria we look for in a drug. I’d like to thank those involved in this study and we look forward to developing PXS25 further.”
Additional phase I trials will be completed before PXS25 is evaluated in patients with lung disease. PXS25 is being developed as a potential new treatment for pulmonary fibrosis.